Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab
- 10 August 2009
- journal article
- case report
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 15 (8), 1006-1008
- https://doi.org/10.1177/1352458509106512
Abstract
In neuromyelitis optica (NMO), the monoclonal B-cell antibody rituximab is a therapeutic option. Little is known about the course of NMO and the safety of rituximab during pregnancy. In this study, we report the clinical course of a patient with NMO after application of rituximab 1 week before inadvertent conception. Mother and child did not experience any adverse event, and the postpartum development of the baby was completely normal up to 15 months. Clinical course of NMO was stable during the entire pregnancy. This case illustrates a favorable outcome in a pregnant NMO patient and her child after therapy with rituximab.Keywords
This publication has 7 references indexed in Scilit:
- Pregnancy and rheumatic disease: “by the book” or “by the doc”Clinical Rheumatology, 2008
- How effective is intravenous immunoglobulin for the treatment of relapsing-remitting multiple sclerosis?Nature Clinical Practice Neurology, 2008
- Pregnancy and autoimmunity: Maternal treatment and maternal disease influence on pregnancy outcomeAutoimmunity Reviews, 2005
- Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosisZeitschrift für Neurologie, 2004
- The clinical course of neuromyelitis optica (Devic’s syndrome)Neurology, 1999
- Rate of Pregnancy-Related Relapse in Multiple SclerosisNew England Journal of Medicine, 1998
- Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?Immunology Today, 1993